Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Reset

Disease Cell Type Therapeutic or Technology Institution Stage Project Objective Details
Heart Disease, Heart failure Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Tenaya Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Immune Disease Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Tr1X Inc.
Clinical Trial, Phase 1 or Phase 1/2
Autoimmune Disorder, Lupus, Systemic Lupus Erythematosus (SLE) iPS Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Fate Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) Somatic Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Senti Bio
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) Adult or Tissue Stem Cell Biologic, Gene modification, Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 3
Blood Disorders Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Nexcella, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Parkinson's Disease iPS Cell Personalized cell therapy, Therapeutic Approach Aspen Neuroscience
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Allogene Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Age-related macular degeneration, Vision Loss Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Luxa Biotechnology
Clinical Trial, Phase 1 or Phase 1/2
Danon Disease, Metabolic Disorders, Pediatrics Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Rocket Pharmaceuticals, Inc.
Clinical Trial, Phase 2
Developmental Disorders, Neurological Disorders, Spina Bifida Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UC Davis
Clinical Trial, Phase 2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Other Gene Therapy (All), Gene Therapy, cell free, Nucleic acid based therapy, Therapeutic Approach UCSD
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Melanoma, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Kidney Disease Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 1 or Phase 1/2
Age-related macular degeneration, Vision Loss Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Regenerative Patch Technologies LLC
Clinical Trial, Phase 2
HIV/AIDS, Infectious Disease Other Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage, Vision Loss Adult or Tissue Stem Cell Biologic, Exosomes based therapy, Therapeutic Approach Combangio
Clinical Trial, Phase 2
Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Neurological Disorders, Vision Loss Somatic Cell Personalized cell therapy, Therapeutic Approach Immusoft Corporation
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Eureka Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders Adult or Tissue Stem Cell Antibody, Biologic, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Blood Cancer, Cancer Somatic Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Angiocrine
Clinical Trial, Phase 3
Bone or Cartilage Disease, Osteoarthritis Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Genascence Corporation
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders Somatic Cell Cell processing & handling, Immune tolerance/management, Technology COH
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders, Bone Marrow Transplant and Viral Infection Adult or Tissue Stem Cell Immune tolerance/management, Technology Stanford
Clinical Trial, Phase 1 or Phase 1/2
Epilepsy, Neurological Disorders Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Neurona Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS, Infectious Disease Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Excision BioTherapeutics
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, IPEX Syndrome Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Muscle Injury, Skeletal/Smooth Muscle disorders Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach UC Davis
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach BioEclipse Therapeutics INC.
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Heart Disease, Heart failure Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Blood Cancer, Cancer, Leukemia, Leukemia, Acute Myeloid (AML) Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Stroke Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Amyotrophic Lateral Sclerosis, Neurological Disorders Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS, Immune Disease, Infectious Disease Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Parkinson's Disease Vital Research Opportunity Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Brain Neurotherapy Bio
Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage, Vision Loss Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Breast Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Retinitis Pigmentosa, Vision Loss Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Cystinosis, Kidney Disease, Kidney Failure, Metabolic Disorders Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSD
Clinical Trial, Phase 1 or Phase 1/2
Diabetes, Metabolic Disorders, Type 1 diabetes Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Severe Combined Immunodeficiency, X-linked (X-SCID) Adult or Tissue Stem Cell Antibody, Biologic, Therapeutic Approach Jasper Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Kidney Disease, Kidney Failure Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Bone Marrow Transplant and Viral Infection Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach CHLA
Clinical Trial, Phase 1 or Phase 1/2
1 2 3 4 5
Displaying 151 – 200 of 232